Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-03-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（可钰）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements about qualifications, compliance with laws and regulations, independence, and commitments during tenure. There are no financial statements, earnings data, or report summaries. It is not an announcement of a report publication but a formal declaration related to board/management matters. This fits the category of Board/Management Information (MANG), which covers announcements related to changes or appointments in the company's board or senior management.
2024-03-25 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2023年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2023 of a company, with an independent verification opinion issued by the sponsoring securities firm. It discusses the company's internal control systems, evaluation scope, standards for identifying internal control deficiencies, and the conclusion that no major deficiencies exist. The document is detailed, over 9,000 characters, and contains substantive content about internal control evaluation, not just an announcement or certification. It is not a full annual report or audit report but specifically focuses on internal control evaluation and the verification opinion by the sponsor. This fits the definition of an Audit Report / Information (AR), which includes audit reports, applied accounting principles, and internal control evaluation results, excluding full annual reports. Therefore, the document is best classified as AR with high confidence. FY 2023
2024-03-25 Chinese
2023年度独立董事述职报告（王京宝）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from a specific independent director of the company. It details the director's duties, attendance at board and shareholder meetings, opinions on various company matters, committee participation, and overall evaluation and suggestions. The content focuses on the director's report on their annual performance and responsibilities rather than financial results or audit opinions. It is not a full annual report (10-K), audit report (AR), or interim report (IR). It is also not an announcement or proxy solicitation. The document is a formal report by an independent director on their annual duties and opinions, which fits best under Board/Management Information (MANG) as it relates to management and board-level disclosures about governance and director activities.
2024-03-25 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "新天地药业股份有限公司2023 年年度报告全文" which translates to "Newland Pharmaceutical Co., Ltd. 2023 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and a full financial report section. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial statements, management analysis, and detailed business descriptions. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-03-25 Chinese
董事会提名委员会关于提名非独立董事、独立董事候选人的审核意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the Board Nomination Committee regarding the nomination of non-independent and independent director candidates for the company's sixth board. It references compliance with company law and internal governance rules, and it is focused on board member nominations. There is no financial data, earnings information, or report publication mentioned. The content is about board/management information, specifically nominations for the board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2024-03-25 Chinese
第五届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 5th Board of Directors of 新天地药业股份有限公司. It includes approval of the 2023 Annual Report and its summary, the 2023 Board of Directors work report, the 2023 General Manager work report, the 2023 financial statements, internal control self-evaluation report, fundraising usage report, profit distribution plan, remuneration plans for directors and senior management, credit facility applications, cash management, appointment of auditors, board election nominations, and other governance matters. The document repeatedly states that these reports and detailed contents are disclosed separately on the official disclosure website (巨潮资讯网) and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself is a meeting resolution announcement, not the full annual report or financial statements. It is a formal board meeting resolution announcement covering multiple governance and financial reporting topics, including board changes and remuneration. Given the comprehensive nature of board decisions and nominations, and the focus on board meeting resolutions, the best fitting category is Board/Management Information (MANG). The document is not a full annual report (10-K), nor a simple voting result announcement (DVA), nor a report publication announcement (RPA). It is a board meeting resolutions announcement covering management and governance matters.
2024-03-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.